Table 1.
Patient and Disease Characteristics
| Characteristic | Study Group
|
Control
|
P-Value |
|---|---|---|---|
| Number n = 56 (%) |
Number N = 161 (%) |
||
| Sex | |||
| Male | 40 (71) | 95 (59) | .11 |
| Female | 16 (29) | 66 (41) | |
| Median age (years) | 43.5 (range: 18–70) | 51 (range: 20–71) | .01 |
| Diagnosis | |||
| AML/MDS | 23 (41) | 69 (43) | .87 |
| ALL | 9 (16) | 18 (11) | |
| Lymphoma | 12 (21) | 38 (24) | |
| Hodgkin disease | 4 (7) | 12 (7) | |
| CML | 3 (5) | 11 (7) | |
| CLL | 1 (2) | 5 (3) | |
| Multiple myeloma | 2 (4) | 8 (5) | |
| Systemic sclerosis | 2 (4) | 0 (0) | |
| Disease status* | |||
| Low risk | 9 (16) | 23 (14) | .75 |
| Intermediate risk | 14 (25) | 49 (30) | |
| High risk | 33 (59) | 89 (55) | |
| Donor type | |||
| Related | 28 (50) | 91 (57) | .43 |
| HLA-matched | 23 (41) | 85 | |
| HLA-mismatched | 5 (9) | 6 | |
| Unrelated | 28 (50) | 70 (43) | |
| HLA-matched | 23 (41) | 62 | |
| HLA-mismatched | 5 (9) | 8 | |
| Preparative regimens | |||
| Myeloablative, | 21 (37) | 59 | 1.00 |
| RIC | 35 (62) | 102 | |
| Pre-allo-HSCT LVEF (%) | |||
| >50 | 0 | 161 | .0001 |
| ≤45 | 25 (45) | ||
| ≤40 | 21 (37) | ||
| ≤35 | 10 (18) | ||
| Risk factors for cardiac complications† | |||
| Yes | 35 (62.5) | 97 (60) | .87 |
| No | 21 (37.5) | 64 (40) | |
| Cyclophosphamide in preparative regimen | |||
| Yes | 17 (30) | 39 (24) | .37 |
| No | 39 (70) | 122 (76) | |
RIC indicates reduced-intensity conditioning; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; LVEF, left ventricular ejection fraction; MDS, myelodysplastic syndromes.
Low-risk: CML chronic phase #1, CR1 for all other diseases; Intermediate-risk: CML in equal to or greater than second chronic phase, CR2 or beyond for all other diseases; High risk: CML in accelerated or blast phase; relapsed or refractory disease for all other diseases.
Risk factors include smoking, hypertension, hyperlipidemia, coronary artery disease, arrhythmia, myocardial infarction, or congestive heart failure.